Dermatopathology and Diagnostics

From the first glance under the scope to the final sign-out, Dermatopathology & Diagnostics is where clinical questions meet microscopic truth. This session page is designed for dermatologists, pathologists, trainees, and allied professionals who want to sharpen recognition of inflammatory patterns, distinguish neoplasms with confidence, and integrate new tools without losing the basics. You’ll move from pattern analysis (spongiotic, lichenoid, interface, granulomatous, vesiculobullous) to entity-level clarity, learning when to rely on H&E and when to escalate to IHC, DIF, or molecular assays. Because many attendees arrive while planning their next learning calendar, we also include discovery terms like Dermatology Conference to help this page surface when professionals search for meetings they can actually attend. The curriculum connects everyday clinic questions—“Is this psoriasis, eczematous dermatitis, or drug eruption?”—to the laboratory decisions that confirm or refute the working diagnosis, while emphasizing turnaround time, sampling adequacy, and communication etiquette between clinicians and the lab. We highlight the enduring centrality of clinicopathologic correlation, showing how targeted histories (drug timelines, distribution, pruritus, mucosal involvement, systemic flags) change the slide you cut, the stain you order, and the conclusion you reach. Emerging technologies—whole-slide imaging, AI-assisted triage, LC-OCT, reflectance confocal microscopy, and high-frequency ultrasound—are addressed pragmatically: what to expect today, what is coming next, and how to avoid overcalling artifacts as disease. Equally important, we cover specimen handling, site selection, and “don’t-miss” pitfalls such as sampling the edge of a blister, preserving tissue for DIF, and notching melanocytic lesions appropriately for margin assessment. By the end, participants will read patterns faster, write more actionable reports, and embed a shared language that improves clinic–lab feedback loops, reduces repeat biopsies, and drives safer, earlier treatment decisions across inflammatory, infectious, and oncologic dermatology.